News

10x Genomics Unveils Affordable Single Cell Solutions

10x Genomics Unveils Affordable Single Cell Solutions

10x Genomics Introduces Revolutionary Single Cell Products

10x Genomics, Inc. (Nasdaq: TXG), a frontrunner in single cell and spatial biology, has made a significant stride by introducing its latest products, GEM-X Flex and GEM-X Universal Multiplex. These innovations aim to make single cell analysis more accessible and affordable for researchers across various fields, reflecting a commitment to democratizing scientific research.

Enhanced Accessibility Through Innovation

The launch of the GEM-X series underscores 10x Genomics' strategic goal to lower costs associated with single cell analysis. By reducing expenses on multiple fronts—per cell, per sample, per experiment, and per project—the company intends to empower more researchers. This initiative responds to the increasing demand for high-throughput single cell applications, providing both new and established labs with the tools necessary for advancement.

The Vision Behind GEM-X Products

Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics, emphasizes the significance of these launches in advancing single cell research. "We aim to make single cell analysis more feasible for a wider community of researchers than ever before. The innovations introduced this year with the GEM-X line are set to enhance research capabilities dramatically," he states.

GEM-X Flex: Leading the Way in Performance

The GEM-X Flex Gene Expression assay is designed to deliver unparalleled performance combined with remarkable cost efficiency. This innovative technology transitions 10x Genomics' highest-performing assay, Chromium Flex, into the GEM-X platform. As a result, researchers can engage in extensive single cell analyses without financial strain.

Key Features of GEM-X Flex

  • Unmatched Flexibility: Researchers can schedule fixes, batches, and runs at their convenience without sacrificing data quality.
  • Mega-Scale Capabilities: The system can profile up to 2.5 million cells per run, allowing significant insights at minimal costs.
  • Diverse Sample Compatibility: This assay can analyze a wide range of samples, including fresh, frozen, and various fixed tissues.
  • Improved Sample Recovery: Low input cell recommendations promote better sample utilization, crucial for projects using limited biospecimens.

Niels Vandamme, Head of VIB Single Cell Core, also praises GEM-X Flex, highlighting how it provides a more reliable preservation method for biological samples. The advantages offered by this workflow open new avenues for research.

GEM-X Universal Multiplex: Efficient and Cost-Effective

Another groundbreaking introduction, the GEM-X Universal Multiplex, marks a game-changer for researchers interested in cost-effective studies. This system enables on-chip multiplexing, allowing scientists to examine multiple samples simultaneously while streamlining the workflow.

Standout Attributes of GEM-X Universal Multiplex

  • High Data Quality: The performance is consistent with the established GEM-X protocols, ensuring reliable results for all studies.
  • Affordable Single Cell Analysis: Researchers can conduct studies for about $560 per sample, making this option broadly accessible.
  • Versatile Sample Types: It accommodates various species and sample types, increasing the range of potential research applications.
  • Streamlined Workflow: The innovative design eliminates the need for additional sample tagging, enhancing productivity.

The GEM-X Universal 3' and 5' Gene Expression Multiplex assays are now available for orders, paving the way for flexible and scalable single cell research. Researchers who engage with this technology can expect unparalleled efficiency in their projects.

About 10x Genomics

10x Genomics is committed to developing life science technologies aimed at unraveling the intricacies of biology. Their comprehensive solutions combine devices, consumables, and software, catering to academic, translational research, and biopharmaceutical inquiries. Through these innovative products, significant strides are made in fields like oncology, immunology, and neuroscience. Their ongoing dedication to improving our understanding of biology and health is reshaping scientific research.

Frequently Asked Questions

What are the new products introduced by 10x Genomics?

10x Genomics has launched two innovative products: GEM-X Flex and GEM-X Universal Multiplex, designed to enhance single cell analysis.

How does GEM-X Flex improve cost efficiency for researchers?

The GEM-X Flex technology allows researchers to run extensive experiments at a lower cost per cell, facilitating larger studies without financial burdens.

What types of samples can be analyzed using GEM-X products?

GEM-X products can analyze a wide range of samples, including fresh, frozen, and FFPE tissues, broadening research possibilities.

Why is the GEM-X Universal Multiplex significant?

The GEM-X Universal Multiplex enables on-chip multiplexing, significantly lowering costs while streamlining the analysis process for multiple sample types.

How can researchers leverage these new technologies?

Researchers can utilize these products to expand their studies in single cell analysis, increasing both the scope and efficiency of their research endeavors.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

NEXT Properties Exchange Offers: The Full Breakdown

Updated Category News Views 21

What's the Deal with These Exchange Offers? You know, nothing says 'we're changing things up' like an exchange offer. So what did NEXT Properties do? Well, they laid down two offers for the books on their outstanding 6.950% and 6.390% senior notes, due in 2044 and 2050, respectively. These are getting swapped out for some fresh 7.731% senior sustainability-linked notes...

Continue Reading
CardVault by Tom Brady Expands to Pittsburgh

Updated Category News Views 4

Tom Brady’s CardVault Hits Pittsburgh’s Historic Strip District Pittsburgh just got another feather in its cap with CardVault by Tom Brady marking its 20th store at The Terminal. As if this city needed more sports excitement! Pittsburgh, with its die-hard Steelers, Penguins, and Pirates fans, snags a premium spot for sports collectibles. A Prime Spot for Serious...

Continue Reading
What's Brewing: Vinitaly Forum Maps US Wine Scene

Updated Category News Views 5

Exploring the U.S. Market Challenges for Italian Wine Imagine sipping on Chianti while overhearing insiders dish about the wine game in America. That's what the Vinitaly Business Forum is set to unfold this October at Pier 36, NYC. This isn't your typical wine and cheese night; it's a power-packed showdown, aligning Italian wineries with North American players who hold...

Continue Reading
Saab Q3 2026: Major Contracts Fuel Impressive Growth

Updated Category News Views 6

Saab's Stellar Q3 Performance If there’s one picture capturing the essence of Saab’s third quarter in 2026, it's one brimming with contracts, cash, and sheer growth. They’re racking up tangible wins left and right, and if you're an investor who loves numbers doing a solid 30.6% high jump, Saab's buzzing red-hot. Key Contracts Putting Saab in the Spotlight The very...

Continue Reading
Basic Invite's Holiday Card Service Offers Saving Time

Updated Category News Views 6

Getting the Cards Out: Maneuvering the Holiday Hustle Alright, let's dive into the madness that is holiday card season. Could be a logistical nightmare or a nostalgic tradition, depending on your cup of tea. Basic Invite here is trying to cut through the chaos by bumping deadlines and offering some straight-out-the-gate mailing options. If you play your cards right—pun...

Continue Reading
Netcapital's Revenue Fraud Scandal Hits Investor Confidence

Updated Category News Views 4

The Rise and Fall of Netcapital: A Troubling Drop Netcapital Inc. (NASDAQ: NCPL) has found itself in hot water with investors after revelations of a wild scheme to fluff up its revenue figures. It’s like watching a house of cards crumble — and investors are left holding the bag. From December 15, 2021, through September 3, 2026, a slew of misinformation allegedly...

Continue Reading
First Citizens Surprises with Q3 Gains and Buyback Plan

Updated Category News Views 5

Unexpected Third Quarter Tailwinds for First Citizens There are days in this trading gig when a bank I'll barely sneeze at hits out of the park. First Citizens BancShares (NASDAQ:FCNCA) pulled off such a feat, wringing out a third-quarter 2026 performance that beat their own benchmarks. They threw $600 million back to shareholders in repurchased stocks while repaying an...

Continue Reading
Gala Spotlights Veterans' Mental Health Support

Updated Category News Views 11

Champions for Veterans Honored at Headstrong Gala If you ever wondered who stands in the trenches alongside veterans facing mental health battles, this year's Headstrong Gala offered a crystal-clear answer. Held on October 16 at Pier Sixty in New York City, this shiindig wasn’t just about schmoozing over canapés. It was about celebrating the grit and guts of those...

Continue Reading
dMY IV Settlement: Investor Rights and Key Dates

Updated Category News Views 5

dMY IV Settlement: What You Need to Know Listen up, folks! If you've got a stake in dMY Technology Group, Inc. IV, there's big news brewing. We're talking class action, settlement talks, and a cool $11 million on the line. Let's crack open what this means for you as a holder of dMY IV Class A common stock during December 2021's whirlwind. Who Can Get a Piece of the...

Continue Reading
Salus Scientific Pioneers Safety at TCT 2026

Updated Category News Views 5

Revolutionizing Occupational Safety in Healthcare Radiation exposure in the medical field: the dull, ominous toll it takes on healthcare professionals, often cloaked in acceptance as a mere occupational hazard. But here's Salus Scientific crashing into the party at TCT 2026 like a seasoned rockstar, demanding we stop accepting the dangers of fluoroscopy-guided procedures...

Continue Reading

Top 5 Most Recently Viewed Articles

Octopus AIM VCT plc Updates Net Asset Valuation for Investors

Updated Category News Views 127

Octopus AIM VCT plc Updates on Net Asset Value Octopus AIM VCT plc has recently shared an important update regarding the unaudited net asset value (NAV) of its Ordinary shares. As of a recent assessment, the NAV stands at approximately 47.7 pence per share, providing valuable insights for investors and stakeholders alike. Understanding the NAV is crucial as it reflects...

Continue Reading
Boku Experiences Strong Growth Trajectory in Recent Update

Updated Category News Views 282

Boku's Positive Performance Drives Stock Growth Shares of Boku (NASDAQ: BOKU) experienced an increase of 1.8% following the release of a promising trading update for the fiscal year. This positive momentum highlights the company's resilience even in the face of foreign exchange fluctuations. Significant Growth in Total Payment Volume The mobile payments provider reported...

Continue Reading
New Leadership Appointment in Admirals Group: Key Changes Ahead

Updated Category News Views 184

Leadership Restructuring at Admirals Group AS The Supervisory Board of Admirals Group AS has made a significant change to its Management Board by appointing Mrs. Liudmila Bataeva as a new member, effective October 1, 2025. This decision marks an important step in the company’s strategic development as it continues to adapt and innovate in the financial services sector....

Continue Reading
AeroVironment Launches P550: A New Standard for UAS Mobility

Updated Category News Views 146

AeroVironment Unveils the P550: A Game-Changer for UAS AeroVironment (NASDAQ: AVAV) has revealed its latest innovation, the P550, an advanced autonomous Group 2 eVTOL uncrewed aircraft system (UAS) that promises to redefine battlefield adaptability and operational capabilities for military forces. By harnessing a Modular Open Systems Approach (MOSA) alongside AI-driven...

Continue Reading
Cameco Supports Westinghouse's Technology Licensing Agreement

Updated Category News Views 154

Cameco's Support for Westinghouse's New Resolution Recently, Cameco (TSX: CCO; NYSE: CCJ) expressed its enthusiasm regarding the successful resolution of the intellectual property dispute involving Westinghouse Electric Company. This dispute included key players from Korea, specifically Korea Electric Power Corporation and Korea Hydro & Nuclear Power Co., Ltd.,...

Continue Reading